Ney Carter Borges: The APERITIF Trial Clarifies Rivaroxaban’s Role in LVT
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn about a recent article by Etienne Puymirat et al in JAMA Cardiology:
”The APERITIF randomized clinical trial evaluated whether adding low-dose rivaroxaban (2.5 mg twice daily for 4 weeks) to dual antiplatelet therapy (DAPT) reduces left ventricular (LV) thrombus formation after anterior ST-segment elevation myocardial infarction (STEMI).
LV thrombus remains a clinically significant complication due to its association with systemic embolism, stroke, and mortality, particularly in large anterior infarctions.
Contemporary data suggest LV thrombus incidence may reach 15–25% in anterior MI when assessed with cardiac magnetic resonance (CMR), the gold-standard imaging modality .
In this multicenter PROBE-design trial conducted across 29 French centers, 560 patients (mean age 61.1 ± 11.6 years; 21.6% women) were randomized to DAPT plus rivaroxaban (n=277) or DAPT alone (n=283).
The primary endpoint was LV thrombus detected by contrast-enhanced CMR at 1 month. LV thrombus occurred in 13.7% of patients receiving rivaroxaban versus 16.6% with DAPT alone (absolute difference −2.9%; 95% CI −8.9% to 3.2%; P=0.34), indicating no statistically significant reduction .
Major adverse cardiovascular events were low and comparable (0.7% vs 1.1%).
Major bleeding (BARC ≥2) was infrequent and similar between groups (1.5% vs 0.7%), but minor bleeding (BARC 1) was significantly higher with rivaroxaban (16.4% vs 7.2%; difference 9.3%; 95% CI 3.6%–14.8%) .
In conclusion, low-dose rivaroxaban added to DAPT did not significantly reduce LV thrombus formation at 1 month but increased minor bleeding.
Given lower-than-expected event rates, the study may have been underpowered; thus, modest benefit cannot be excluded.”
Title: Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
Authors: Etienne Puymirat, Gilles Soulat, Benoit Lattuca, Claire Bouleti, Nicolas Delarche, François Roubille, Yves Cottin, Didier Bression, Nicolas Combaret, Edouard Gerbaud, Thibaut Lhermusier, Loic Biere, Olivier Dubreuil, Elie Mousseaux, Philippe Gabriel Steg, Guillaume Cayla, Gilles Lemesle, Johanne Silvain, Jean-Guillaume Dillinger, Jean-Louis Georges, Grégory Ducrocq, Thibaud Genet, Jean-François Morelle, Gilles Montalescot, Laurence Berard, Alexandra Rousseau, Maxime Soen, Tabassome Simon, Nicolas Danchin for the APERITIF study investigators
Read the Full Article on JAMA Cardiology
Stay updated on all scientific advances with Hemostasis Today.
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires
-
May 27, 2026, 17:51Nita Radhakrishnan: Post Graduate Institute of Child Health Receives WFH Data Quality Certification for Excellence
-
May 27, 2026, 17:51Fiona Robinson: What exactly Are Rebalancing Agents for Bleeding Aisorders?
-
May 27, 2026, 17:14Khurram Nasir: Can Earlier LDL-C Lowering Change the Trajectory of Cardiovascular Disease?